Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

nimotuzumab 1gimeracil 1endostar protein 1Radiotherapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Esophageal × Clear all
NCT02749526 2022-07-29

Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Terminated
70 enrolled
Gastrointestinal

Esophageal

NCT02591784 2022-03-17

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
42 enrolled
Gastrointestinal

Esophageal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡